Journey Medical Corporation
- Capitalisation boursière
- $204.1M
- Volume
- 168K
- Prochaine publication des résultats
- Nov 11, 2026
Journey Medical Corporation (DERM) : cours, analyse et données
Valeur intrinsèque
Prévisions des analystes
Prévisions boursières →Derniers résultats
| Signalé | Écart estimé | Changement d’une année sur l’autre | |
|---|---|---|---|
| Chiffre d’affaires | $15.96M | n/a | +21.48% |
| EPS | -$0.01 | +$0.01 | +93.75% |
Métriques
- Cours acheteur
- 5.17
- Chiffre d’affaires (ttm)
- 68.2M
- Résultat net (ttm)
- -6.1M
- 1.10
- -0.22
- n/a
- -120.5
- P/B (ttm)
- 6.23
- P/S (ttm)
- 2.99
- Date des résultats
- Nov 11, 2026
- Cours vendeur
- 9.24
- Volume
- 167,997
- Volume moy. (20D)
- 242,456
- Ouverture
- 7.18
- Clôture précédente
- 7.09
- Fourchette du jour
- 7.06 - 7.41
- Intervalle de 52 semaines
- 4.31 - 9.55
- Analyste
- n/a
- Objectif de prix
- n/a
- Dividendes
- n/a
- Date ex-dividende
- n/a
À propos de Journey Medical Corporation
Voir le profil →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.